Abstract 73P
Background
Cabozantinib (C), a tyrosine kinase inhibitor against VEGFR2, RET, MET and Axl, has demonstrated clinical activity in RCC and 2L HCC, and has been shown to promote an immune-permissive environment. C is being investigated in clinical trials in combination with immune checkpoint inhibitors (ICI). This preclinical study aimed to determine systemic cytokine profile changes induced by the combination of C + αPD1 and assess cooperativity in anti-tumoral effects.
Methods
Syngeneic colon (CT26, Colon38) and bladder (MBT2) tumour models were established in BALB/C, C57Bl6 or C3H/HEJ mice. C (10 or 30 mg/kg po qd) and αPD1 (10 mg/kg ip 2x weekly) were administered either simultaneously for up to 30 days or with a 14-day delay for αPD1, and serum was collected.
Results
After 30 days' coadministration of C (30 mg/kg) and αPD1, serum cytokines and chemokines (VEGFA, IL3, GM-CSF, MIP1beta, IL17, CCL5, IFNγ, IL10, IL5) were elevated with a median of 72x (range 39–1207x), as compared to 30-days' single administration of αPD1 or C with a median of 3.7x (1.4–135x) and 1.0x (0.5–1.9x), respectively, relative to vehicle-treated animals. Delayed treatment with αPD1 did not result in the same increase in analyte levels as coadministration (median of 1.74x [1–9.9x]). For anti-tumour efficacies, two C doses were explored in CT26 (T/C10/30 67/38% - tumour growth inhibition T/C ratios at 10 or 30 mg/kg), MBT2 (T/C10/30 37/14%) and Colon38 (T/C10/30 21/12%) models. C at 30 mg/kg led to strong anti-tumour efficacy in MBT2 and Colon38, limiting any ICI combinatorial impact to the post-treatment tumour expansion. For CT26 (30 mg/kg) and MBT2 (10 mg/kg), simultaneous dosing of C and αPD1 showed greater anti-tumour effects than single agents despite only limited effects of αPD1 alone. C + αPD1 more than doubled the treatment-specific time that tumours required to reach 1000mm3 compared to C alone.
Conclusions
The results indicate that simultaneous treatment of C + αPD1 leads to strong systemic increases in key cytokines and chemokines and can result in robust anti-tumour efficacy. Our results support the clinical exploration of C + ICI combinations and the potential of this TKI for use in further clinical settings.
Clinical trial identification
Editorial acknowledgement
Isabelle Kaufmann, PhD of Oxford PharmaGenesis, Oxford, UK for provided medical writing support, which was sponsored by Ipsen, Abingdon, UK.
Legal entity responsible for the study
Ipsen.
Funding
Ipsen.
Disclosure
R. Sparks: Full / Part-time employment: Ipsen. S. Rolland: Full / Part-time employment: Ipsen. S. Klinz: Full / Part-time employment: Ipsen. F. Meyer-Losic: Full / Part-time employment: Ipsen. J. Nakhle: Full / Part-time employment: Ipsen. R. Delille: Full / Part-time employment: Ipsen. M. Hillairet de Boisferonc: Research grant / Funding (institution), Contractual obligation: Ipsen.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract